MJA
MJA

Improving the effectiveness of clinical medicine: the need for better science

Med J Aust 2012; 196 (5): 304-308. || doi: 10.5694/mja11.10364
  • Ian A Scott1
  • Paul P Glasziou2

  • 1 Department of Internal Medicine and Clinical Epidemiology, Princess Alexandra Hospital, Brisbane, QLD.
  • 2 Centre for Research in Evidence-based Research, Bond University, Gold Coast, QLD.


Competing interests:

No relevant disclosures.

  • 1. National Health and Hospitals Reform Commission. A healthier future for all Australians: final report June 2009. Canberra: Department of Health and Ageing, 2009.
  • 2. Olsen L, Aisner D, McGinnis JM. Institute of Medicine Roundtable on Evidence-based Medicine. The learning healthcare system: workshop summary. Washington, DC: National Academies Press, 2007.
  • 3. National Institute for Health and Clinical Excellence. Putting guidance into practice. http://www.nice.org.uk/usingguidance/ (accessed Nov 2011).
  • 4. Jelinek GA, Neate SL. The influence of the pharmaceutical industry in medicine. J Law Med 2009; 17: 216-223.
  • 5. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet 2000; 355: 2037-2040.
  • 6. Mitchell RJ, McClure RJ, Olivier J, Watson WL. Rational allocation of Australia’s research dollars: does the distribution of NHMRC funding by National Health Priority Area reflect actual disease burden? Med J Aust 2009; 191: 648-652. <MJA full text>
  • 7. Glasziou PP. Promoting evidence-based non-drug interventions: time for a non-pharmacopoeia? Med J Aust 2009; 191: 52-53. <MJA full text>
  • 8. Sharpe N. Clinical trials and the real world: selection bias and the generalisability of trial results. Cardiovasc Drugs Ther 2002; 16: 75-77.
  • 9. Abernethy AP, Raman G, Balk EM, et al. Systematic review: reliability of compendia methods for off-label oncology indications. Ann Intern Med 2009; 150: 336-343.
  • 10. Scott IA. Non-inferiority trials — determining when alternative treatments are good enough. Med J Aust 2009; 190: 326-330. <MJA full text>
  • 11. Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA 2009; 302: 2679-2685.
  • 12. Fenton M, Leitch A, Grindlay D. Developing a UK DUETs module 2009. www.lindalliance.org/pdfs/UK_DUETs/DEVELOPING_A_UK_DUETs%20_MODULE_2009.pdf (accessed Feb 2011).
  • 13. Dear RF, Barratt AL, McGeechan K, et al. Landscape of cancer clinical trials in Australia: using trial registries to guide future research. Med J Aust 2011; 194: 387-391. <MJA full text>
  • 14. National Institute for Health Research. Transforming health research: the first two years. Progress report 2006–2008. London: NIHR, 2008. http://www.nihr.ac.uk/files/pdfs/NIHR%20Progress%20Report%202006-2008.pdf (accessed Nov 2011).
  • 15. Department of Health and Human Services. Text of the Recovery Act related to comparative effectiveness funding. Excerpt from the American Recovery and Reinvestment Act 2009. March 2009. http://www.hhs.gov/recovery/programs/cer/recoveryacttext.html(accessed Mar 2011).
  • 16. Garattini S, Chalmers I. Patients and the public deserve big changes in evaluation of drugs. BMJ 2009; 338: b1025.
  • 17. Glasziou PP. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category. Med J Aust 1995; 162: 33-36.
  • 18. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials. Increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 1624-1632.
  • 19. Yusuf S. Damage to important clinical trials by over-regulation. Clin Trials 2010; 7: 622-625.
  • 20. Relton C, Torgerson D, O’Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. BMJ 2010; 340: c1066.
  • 21. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med 2009; 151: 206-209.
  • 22. Merkow RP, Ko CY. Evidence-based medicine in surgery. The importance of both experimental and observational study designs. JAMA 2011; 306: 436-437.
  • 23. Australian Orthopaedic Association National Joint Replacement Registry. Hip and knee arthroplasty. Annual report 2010. Adelaide: AOA, 2010. http://www.dmac.adelaide.edu.au/aoanjrr/documents/aoanjrrreport_2010.pdf (accessed Jul 2011).
  • 24. Goudie AC, Sutton AJ, Jones DR, Donald A. Empirical assessment suggests that existing evidence could be used more fully in designing randomised controlled trials. J Clin Epidemiol 2010; 63: 983-991.
  • 25. Robinson KA, Goodman SN. A systematic examination of the citation of prior research in reports of randomized, controlled trials. Ann Intern Med 2011; 154: 50-55.
  • 26. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009; 374: 86-89.
  • 27. Scott IA, Greenberg PB; IMSANZ EBM Working Group. Cautionary tales in the clinical interpretation of therapy trial reports. Intern Med J 2005; 35: 611-621.
  • 28. Groenwold RH, Van Deursen AM, Hoes AW, Hak E. Poor quality of reporting confounding bias in observational intervention studies: a systematic review. Ann Epidemiol 2008; 18: 746-751.
  • 29. Tatsioni A, Bonitsis NG, Ioannidis JP. Persistence of contradicted claims in the literature. JAMA 2007; 298: 2517-2526.
  • 30. Schroter S, Black N, Evans S, et al. What errors do peer reviewers detect, and does training improve their ability to detect them? J R Soc Med 2008; 101: 507-514.
  • 31. Kravitz RL, Franks P, Feldman MD, et al. Editorial peer reviewers’ recommendations at a general medical journal: are they reliable and do editors care? PLoS One 2010; 5: e10072.
  • 32. Emerson GB, Warme WJ, Wolf FM, et al. Testing for the presence of positive-outcome bias in peer review: a randomised controlled trial. Arch Intern Med 2010; 170: 1934-1939.
  • 33. Glasziou P, Meats E, Heneghan C, Shepperd S. What is missing from descriptions of treatment in trials and reviews? BMJ 2008; 336: 1472-1474.
  • 34. Landkroon AP, Euser AM, Veeken H, et al. Quality assessment of reviewers’ reports using a simple instrument. Obstet Gynecol 2006; 108: 979-985.
  • 35. Cobo E, Selva-O’Callagham A, Ribera JM, et al. Statistical reviewers improve reporting in biomedical articles: a randomized trial. PLoS One 2007; 2: e332.
  • 36. Glasziou P, Chalmers I, Altman DG, et al. Taking healthcare interventions from trial to practice. BMJ 2010; 341: c3852.
  • 37. Hlatky MA, Owens DK, Sanders GD. Cost-effectiveness as an outcome in randomized clinical trials. Clin Trials 2006; 3: 543-551.
  • 38. McKibbon KA, Wilczynski NL, Haynes RB. What do evidence-based secondary journals tell us about the publication of clinically important articles in primary healthcare journals? BMC Med 2004; 2: 33-45.
  • 39. Kent DM, Trikalinos TA. Therapeutic innovations, diminishing returns, and control rate preservation. JAMA 2009; 302: 2254-2256.
  • 40. Alonso-Coello P, Garcia-Franco AL, Guyatt G, Moynihan R. Drugs for pre-osteoporosis: prevention or disease mongering? BMJ 2008; 336: 126-129.
  • 41. Wurtman RJ, Bettiker RL. The slowing of treatment discovery, 1965–1995. Nat Med 1995; 1: 1122-1125.
  • 42. Hopewell S, Clarke MJ, Stewart L, Tierney J. Time to publication for results of clinical trials. Cochrane Database Syst Rev 2007; (2): MR000011.
  • 43. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252-260.
  • 44. Schwartz LM, Woloshin S. Lost in transmission — FDA drug information that never reaches clinicians. N Engl J Med 2009; 361: 1717-1720.
  • 45. US Food and Drug Administration. Law strengthens FDA. 2007. www.fda.gov/oc/initiatives/advance/fdaaa.html (accessed Feb 2011).
  • 46. Coombes R. UK government will tighten the law on trial results after weaknesses found in safety legislation. BMJ 2008; 336: 576-577.
  • 47. European Commission. Medicinal products for human use. Transparency of information related to clinical trials. http://ec.europa.eu/health/human-use/clinical-trials/index_en.htm (accessed Jul 2011).
  • 48. Haines IE, Miklos GLG. Time to mandate data release and independent audits for all clinical trials. Med J Aust 2011; 195: 575-577. <MJA full text>
  • 49. Starr M, Chalmers I, Clarke M, Oxman AD. The origins, evolution and future of the Cochrane Database of Systematic Reviews. Int J Technol Assess Health Care 2009; 25 (Suppl 1): 182-195.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article